Registration categories and fees
Posters Presenting Authors at ECRD
Please do not use the button below, you have been provided a specific registration link via email.
Please note that posters presenting authors do not fall under the speakers category.
of all accepted posters need to REGISTER for the event – paying the full registration fees – and attend the conference.
The authors of the four top scoring posters will be invited to present their poster live at the conference (Monday, 27th June 16:00-17:00 CET). All the other accepted posters will be showcased on the event platform in a multimedia format and made available to all attendees, who will be able to interact directly with authors by chat or by scheduling a meeting.
|Delegate category||Registration Fees|
|EURORDIS members* patients’ organisations and RDI members patients’ organisations||45 €|
|Non-EURORDIS members patients’ organisations||75 €|
|ERN representatives/ academics / healthcare professionals/ researchers / research foundations||150 €|
|EURORDIS Round Table of Companies members**||980 €|
|Healthcare industry, consultants, investors||1225 €|
|Payer bodies/ HTA agencies/ national competent authorities/ regulators/ policy makers or government workers||Complimentary|
|Syndicates / NGOs (not research foundations)||685€|
|Medical Students||45 €|
|Posters Authors at ECRD||Please choose the category that better fits your profile among the ones above|
|Speakers at ECRD||Please do not use the button below, you have been provided a specific registration link via mail by [email protected]|
Healthcare Industry Group Discounts
EURORDIS Round Table of Companies Members: group discount from the 3rd person and above -> 685€
Non-member corporate representatives: group discount from the 3rd person and above -> 855€
To benefit from group discounts, please contact Céline Schwob <[email protected]>
Please contact Stanislav Ostapenko, Communications Manager, EURORDIS (+33 1 56 53 52 61 or [email protected])
Why are corporate donors attending ECRD2022
“We need to make sure that policies are adequately ready. But no one – no payer, no government, no company – can make these changes on its own.”
These words of Dirk Vander Mijnsbrugge from Pfizer, one of the companies supporting the European Conference on Rare Diseases and Orphan Products, confirm the importance of a collaborative effort to address the needs of people with rare diseases.
“There really is no better time than now to rethink and rework the rare disease eco-system and forge meaningful partnerships to drive for greater action.”
Ricardo Marek, President of the Growth & Emerging Markets Business Unit at Takeda, reasserted the urgency of taking action now for the 30 million Europeans living with a rare disease